ENZERNA BIOSCIENCES LLC
Chapel Hill, NC · Biotech · Private
Artificial Site-Specific RNA Endonucleases (ASREs) engineered to target and destroy expanded pathogenic SCA3 mRNAs
- Grants
- $2.8M
- 12 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520162017201820192020202120222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Novel tools for site-specific ablation of the mitochondrial genome | $224,968 | |
| Federal grant | Department of Health and Human Services · Phase I · Novel tools for site-specific ablation of the mitochondrial genome | $224,968 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Creation of animal models of mitochondrial DNA disease for translational research applications | $224,093 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Creation of animal models of mitochondrial DNA disease for translational research applications | $224,093 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeted Degradation of CAG Repeat Expanded Huntingtin mRNA, Associated with Huntington's Disease, Using Artificial Site-Specific RNA Endonucleases | $222,710 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeted Degradation of CAG Repeat Expanded Huntingtin mRNA, Associated with Huntington's Disease, Using Artificial Site-Specific RNA Endonucleases | $222,710 | |
| Federal grant | Department of Health and Human Services · Phase I · Ablation of the pathogenic RNA transcript associated with myotonic dystrophy, DM1 | $223,951 | |
| Federal grant | Department of Health and Human Services · Phase I · Ablation of the pathogenic RNA transcript associated with myotonic dystrophy, DM1 | $223,951 | |
| Federal grant | Department of Health and Human Services · Phase I · Protein-based Therapeutics to treat nucleotide expansion disorders associated with aberrant gene expression | $231,045 | |
| Federal grant | Department of Health and Human Services · Phase I · Protein-based Therapeutics to treatnucleotide expansion disorders associated with aberrant gene expression | $231,045 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of allele-specific protein-based therapeutic targeting the pathogenic RNA associated with Spinocerebellar ataxia type 3 | $259,142 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of allele-specific protein-based therapeutic targeting the pathogenic RNA associated with Spinocerebellar ataxia type 3 | $259,142 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3275 | Lucidicor Inc. | — | — |
| 3276 | DIVINER THERAPEUTICS, LLC | — | — |
| 3277 | VIROGENOMICS BIODEVELOPMENT, INC. | — | — |
| 3278 | ENZERNA BIOSCIENCES LLC | — | — |
| 3279 | Auratus Bio LLC | — | — |
| 3280 | ASKO THERAPEUTICS, INC. | — | — |
| 3281 | UNITED BIOTHERAPEUTICS LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.